Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji MH, Layhadi J, Gieras A, Swoboda I, Zafred D, Keller W, Valent P, Durham SR, Valenta R. Marth K, et al. J Immunol. 2013 Apr 1;190(7):3068-78. doi: 10.4049/jimmunol.1202441. Epub 2013 Feb 25. J Immunol. 2013. PMID: 23440415 Free PMC article.
Tracing antigen signatures in the human IgE repertoire.
Marth K, Novatchkova M, Focke-Tejkl M, Jenisch S, Jäger S, Kabelitz D, Valenta R. Marth K, et al. Mol Immunol. 2010 Aug;47(14):2323-9. doi: 10.1016/j.molimm.2010.05.285. Epub 2010 Jun 22. Mol Immunol. 2010. PMID: 20573403 Free PMC article.
Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A, Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, Stoecklinger A, Marth K, Drescher A, Thalhamer J, Valent P, Majdic O, Valenta R. Gieras A, et al. Among authors: marth k. J Immunol. 2011 May 1;186(9):5333-44. doi: 10.4049/jimmunol.1000804. Epub 2011 Mar 30. J Immunol. 2011. PMID: 21451110
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R, Stegfellner G, Maderegger B, Hauer M, Stolz F, Niederberger V, Marth K, Eckl-Dorna J, Weiss R, Thalhamer J, Blatt K, Valent P, Valenta R. Focke-Tejkl M, et al. Among authors: marth k. J Allergy Clin Immunol. 2015 May;135(5):1207-7.e1-11. doi: 10.1016/j.jaci.2014.09.012. Epub 2014 Nov 13. J Allergy Clin Immunol. 2015. PMID: 25441634 Free PMC article.
Heterogeneity of commercial timothy grass pollen extracts.
Focke M, Marth K, Flicker S, Valenta R. Focke M, et al. Among authors: marth k. Clin Exp Allergy. 2008 Aug;38(8):1400-8. doi: 10.1111/j.1365-2222.2008.03031.x. Epub 2008 Jun 28. Clin Exp Allergy. 2008. PMID: 18564332
Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study.
Eckl-Dorna J, Fröschl R, Lupinek C, Kiss R, Gattinger P, Marth K, Campana R, Mittermann I, Blatt K, Valent P, Selb R, Mayer A, Gangl K, Steiner I, Gamper J, Perkmann T, Zieglmayer P, Gevaert P, Valenta R, Niederberger V. Eckl-Dorna J, et al. Among authors: marth k. Allergy. 2018 May;73(5):1003-1012. doi: 10.1111/all.13343. Epub 2017 Dec 12. Allergy. 2018. PMID: 29083477 Free PMC article. Clinical Trial.
40 results